CONCORD, N.C. — RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol-lowering treatments — NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski‘s No. 6 Ford at this year‘s Daytona […]
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles